Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system.
The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma.
The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers.
It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines.
Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
|IPO Date||Oct 23, 2020|
|CEO||Mr. Adrian H. B. Gottschalk|
500 Technology Square, Suite 700
Cambridge, Massachusetts 02139
|Fiscal Year||January - December|
|Adrian H. B. Gottschalk||President, Chief Executive Officer and Director|
|Dr. Allan Reine M.D.||Chief Financial Officer|
|Dr. Samuel Agresta M.D., M.P.H.||Chief Medical Officer|
|Dr. Gerald R. Crabtree M.d.||Founder and Member of Scientific Advisory Board|
|Dr. Steven F. Bellon Ph.D.||Chief Scientific Officer|
|Ben Strain||Vice President of Investor Relations and Corporate Communications|
|Michael J. LaCascia||Chief Legal Officer|
|Saurabh Sewak Ph.D.||Vice President of Corporate Development|
|Carlos Costa||Chief People Officer|
|Fanny Cavalie||Chief Strategy and Business Operations Officer|
Latest SEC Filings
|Jan 9, 2023||8-K||Current Report|
|Nov 8, 2022||10-Q||Quarterly Report|
|Nov 8, 2022||8-K||Current Report|
|Oct 27, 2022||8-K||Current Report|
|Oct 26, 2022||8-K||Current Report|
|Aug 31, 2022||8-K||Current Report|
|Aug 23, 2022||8-K||Current Report|
|Aug 17, 2022||8-K||Current Report|
|Aug 9, 2022||10-Q||Quarterly Report|
|Aug 9, 2022||10-K/A||[Amend] Annual report|